ArticleEuropean journal of public health2026
Trends in the diagnostic prevalence of cannabis-related disorders and co-occurring psychiatric disorders in adolescents: analysis of German health insurance data from 2013 to 2022.
Article in European journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabis use can have detrimental effects on adolescents' mental health, often co-occurring with child and adolescent psychiatric disorders (CAPD). This study assessed diagnostic prevalence trends in cannabis-related disorders and co-occurring diagnosed CAPD in adolescents receiving outpatient treatment in Germany. Outpatient claims data from the national public health insurance system, covering almost 4 million children and adolescents, were assessed for diagnostic prevalence of cannabis-related disorders (ICD-10 diagnoses F12.X) in insurees aged 12 to 17 years for the years 2013-22, stratified by age group and sex. In addition, the diagnostic prevalence of co-occurring CAPD during the year 2022 was evaluated. From 2013 to 2022, the diagnostic prevalence of cannabis-related disorders among German adolescents utilizing outpatient services increased from 0.08% to 0.10% (+22.4%), with a decline during the COVID-19 pandemic and a higher diagnostic prevalence in older adolescents. Up to 14 years of age, the diagnostic prevalence of cannabis-related disorders was distributed evenly among males and females, while from age 15 onwards, the diagnostic prevalence was higher in males. Overall, 78.3% of adolescents diagnosed with cannabis-related disorders had at least one co-occurring CAPD diagnosis in 2022. Most common co-occurring conditions were depressive disorders, conduct disorders, adjustment disorders, attention-deficit/hyperactivity disorders, and anxiety disorders. Co-occurring depression was particularly often diagnosed, underscoring the urgent need for integrated treatment approaches addressing both disorders simultaneously in this age group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.